Martin Worley Group Makes New Investment in Health Catalyst, Inc. (NASDAQ:HCAT)

Martin Worley Group bought a new position in Health Catalyst, Inc. (NASDAQ:HCAT) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $78,000.

A number of other large investors have also recently modified their holdings of HCAT. Quantbot Technologies LP purchased a new position in shares of Health Catalyst during the 4th quarter worth approximately $29,000. Stoneridge Investment Partners LLC bought a new position in shares of Health Catalyst during the fourth quarter valued at $77,000. Quadrature Capital Ltd purchased a new position in shares of Health Catalyst in the 3rd quarter worth about $84,000. OneAscent Financial Services LLC bought a new position in Health Catalyst in the 4th quarter worth about $97,000. Finally, Virtu Financial LLC purchased a new stake in Health Catalyst during the 4th quarter valued at about $110,000. Institutional investors own 85.00% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on HCAT. Royal Bank of Canada dropped their target price on shares of Health Catalyst from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 27th. Wells Fargo & Company cut their target price on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 21st. Piper Sandler dropped their price objective on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a report on Wednesday, January 8th. Finally, Citigroup lowered their target price on shares of Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.27.

Insiders Place Their Bets

In other news, COO Daniel Lesueur sold 5,209 shares of Health Catalyst stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total transaction of $39,119.59. Following the transaction, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at $685,310.03. The trade was a 5.40 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Benjamin Landry sold 13,827 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $4.55, for a total transaction of $62,912.85. Following the completion of the sale, the general counsel now directly owns 160,437 shares of the company’s stock, valued at $729,988.35. This represents a 7.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 56,530 shares of company stock worth $299,572. Company insiders own 2.50% of the company’s stock.

Health Catalyst Stock Performance

HCAT opened at $4.45 on Thursday. The company’s 50 day moving average is $4.96 and its 200 day moving average is $6.78. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32. The company has a market cap of $312.44 million, a price-to-earnings ratio of -3.30 and a beta of 1.41. Health Catalyst, Inc. has a 12-month low of $3.76 and a 12-month high of $9.24.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.